written on 30.05.2018

Canada Pharma Report May 2018


Topics covered in this new report include healthcare reform – with innovative new pricing models and a move towards outcome-based drug assessment. Additionally, there is a definite shift towards greater regulatory harmonization across Canada’s ten provinces and three territories.


Furthermore, this report unpicks the niches within the pharmaceutical value chain in which Canada is making a name for itself. These include clinical trials and contract research, biotech, genomics and medical device manufacturing. Most eye-catchingly, Canada is forging ahead in new areas such as cannabinoid-based treatments – a topic covered in depth in our special feature on medical cannabis.

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here